Wells Fargo analyst Derek Archila raised the firm’s price target on Kyverna Therapeutics (KYTX) to $31 from $27 and keeps an Overweight rating on the shares after the company announced interim data from the Phase 2 portion of the registrational KYSA-6 clinical trial of KYV-101 in generalized myasthenia gravis. KYV-101’s pivotal programs in MG and stiff person syndrome are “highly de-risked and remain unappreciated by investors,” the analyst argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics Reports Positive Phase 2/3 Trial Data
- Kyverna Therapeutics Reports Positive Phase 2 Trial Results
- Kyverna Therapeutics announces data from Phase 2 from KYSA-6 clinical trial
- Kyverna Therapeutics Advances CAR T-Cell Therapy Study for Myasthenia Gravis
- Kyverna Therapeutics Advances with Promising CAR-T Therapy for Stiff Person Syndrome